Ziconotide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Ziconotide: From Chronic Severe Pain to Migraine Disorder
One-Sentence Summary
Ziconotide is a selective N-type calcium channel blocker historically used as an intrathecal analgesic for severe chronic pain in patients already fitted with an intrathecal pump. The TxGNN model predicts it may also be effective for Migraine Disorder, but this direction is currently supported by only 1 case report and no registered clinical trials, and the drug is not currently marketed in the EU.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented as a formal EU authorization (see below); per the supporting literature, ziconotide is a calcium-channel-blocking analgesic administered intrathecally for chronic severe pain |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A structured mechanism-of-action (MOA) record for ziconotide is not available in this Evidence Pack (flagged as a High-severity data gap). Based on the pharmacological description embedded in the supporting evidence, however, ziconotide is a selective N-type (Cav2.2) voltage-gated calcium channel blocker that inhibits presynaptic release of glutamate, CGRP, and substance P at the dorsal horn of the spinal cord and within the trigeminovascular system. It has historically been delivered intrathecally for the management of chronic severe pain in patients already carrying an implanted intrathecal pump.
Migraine pathophysiology is centrally driven by trigeminovascular nociceptive signaling, in which the same neurotransmitters (glutamate, CGRP, substance P) play a key role. This shared pharmacological target gives the migraine prediction biological plausibility, and is consistent with the mechanistic rationale attached to this indication in the Evidence Pack.
That said, the supporting evidence is limited to a single refractory case report (a patient who already had an intrathecal pump in place for chronic pain and incidentally experienced resolution of chronic migraine). There is no controlled trial evidence, and the highly invasive intrathecal route substantially limits real-world applicability — it would realistically only be relevant to migraine patients who already require an intrathecal pump for another indication, not as a general-purpose migraine therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26392785 | 2015 | Case Report | Journal of Pain Research | Resolution of chronic migraine headaches in a patient receiving intrathecal ziconotide for chronic severe pain; single-patient observation, no controlled comparison |
EU Market Information
Ziconotide currently has no marketing authorization on record for the EU market (0 licenses; market status: Not marketed).
Safety Considerations
No detailed warnings, contraindications, or drug-drug interaction data are currently available in the Evidence Pack (this is flagged as a Blocking-severity gap that prevents a full initial safety assessment). Please refer to the product’s Summary of Product Characteristics (SmPC) or approved labeling, once available, for complete safety information before any further evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction has mechanistic plausibility (shared trigeminovascular neurotransmitter targets) but is currently supported by only a single case report with no controlled clinical trial data, and ziconotide is not marketed anywhere in the EU. Combined with the absence of core safety labeling information (a Blocking-severity data gap), the evidence base is not yet sufficient to advance beyond a research question.
To proceed, the following is needed:
- Retrieval and parsing of the official product label/SmPC (warnings, contraindications, DDI) — currently a Blocking gap
- A structured, sourced mechanism-of-action record for ziconotide (currently a High-severity gap)
- Prospective or at least larger retrospective/case-series data on ziconotide in migraine, given the current evidence is a single case report
- A feasibility assessment of the intrathecal delivery route, since this will restrict any realistic target population to patients who already require an intrathecal pump
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.